SV

Street Verdict

Analyst Scorecard

A record of what ETMarkets Analysis said publicly, with the source. Not advice.

“Short-term traders with a high-risk profile are advised to buy Torrent Pharma stock for a target of ₹3,600 within the next 1-2 months. This call is based on the stock's rebound from its 200-day Exponential Moving Average (EMA) support in June 2025 and a subsequent breakout from a falling trendline resistance on June 27th with high volumes.”

ETMarkets Analysis’s track record (trackable calls only): 193 graded calls · 95% CI 23–35%

Torrent Pharmaceuticals LtdBullishCalled 08 Jul 2025Graded 25 Jul 2025
Verdict:HIT

How this call is judged

A call is judged on closing prices only: a close at its target is a hit and a close at its stop is a miss. A call that states an entry starts at the first close that reaches it; if none does in the days allowed, it was never triggered, is not graded and counts toward no hit rate.

No entry price is stated, so the call starts at the first close after it was published.

Target ₹3,600, as stated.

Window: 60 days, the time frame the call states ("1-2 months").

The target ₹3,600 was reached on a close. Hit.

The grader’s working: R4 TARGET_CALL: entered ₹3353.7 on 2025-07-09 (next trading session's close); target ₹3600 reached at close ₹3603.8 on 2025-07-25. Window 60 days — rule H1: the quote states "1-2 months".

Tracking Torrent Pharmaceuticals Ltd since this call

1-year tracking window
Read the original articleSee ETMarkets Analysis’s full track record